Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BOLD
HOLDBoundless Bio, Inc. · Healthcare · United States · $58M · Avg Vol: $6M/d
41
StockRankGet insider-trade alerts
Q
24
V
35
M
75
P/E (TTM)
—
ROE
-50.2%
D/E
0.6x
Dividend %
—
COMPANY DESCRIPTION
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -3.28 | -2.22 | -3.85 | -2.60 | — | -2.56 | -2.40 | -0.93 | — |
| Shares | 22.2M | 22.2M | 22.3M | 22.4M | +0.8% | 22.5M | — | — | — |
| Debt | 5.2M | 2.2M | 47.6M | 49.0M | 111.5% | 48.3M | — | — | — |
| Equity | -81.7M | -127.1M | 150.6M | 98.7M | -34.5% | — | — | — | — |
| Op CF | -39.6M | -46.9M | -60.8M | -46.7M | — | -47.1M | — | — | — |
| Inv CF | 16.1M | -38.3M | -26.1M | 37.8M | — | — | — | — | — |
| Fin CF | 0.1M | 97.9M | 89.8M | 0.1M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+70.7%
SMA 50SMA 200
Close
$2.51
RSI (14)
82.5
52W High
$2.79
From 52W High
0.9%
SCORE BREAKDOWN
Quality
24
ROIC
-44.0%16.3
ROE
-50.2%17.6
GP/Assets
—N/A
Op. Margin
0.0%40.3
FCF/Assets
-30.1%9.6
Piotroski
12.4
Int. Cover
—N/A
D/E Ratio
0.56x30.0
Current Ratio
9.87x86.9
Value
35
P/E (TTM)
—N/A
EV/EBITDA
-0.2x25.0
P/FCF
—N/A
P/B
0.7x92.6
P/S
—N/A
Div Yield
—N/A
Momentum
75
52W High %
90%81.4
RS 6M
95%96.6
SMA 50/200
1.27x93.0
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+64%59.9
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$58M
P/E (Forward)
-2.7x
Gross Margin
0.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BOLD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BOLD | Boundless Bio, Inc.(you) | $58M | 41 | HOLD |
| LONA | LeonaBio, Inc. | $88M | 33 | SELL |
| FBIO | Fortress Biotech, Inc. | $92M | 49 | HOLD |
| CUE | Cue Biopharma, Inc. | $107M | 33 | SELL |
| CSBR | Champions Oncology, Inc. | $92M | 54 | HOLD |
| AGEN | Agenus Inc. | $126M | 33 | SELL |
| ACET | Adicet Bio, Inc. | $78M | 21 | SELL |
| DTIL | Precision BioSciences, Inc. | $188M | 44 | HOLD |
| 4875.T | MediciNova, Inc. | $62M | 15 | STRONG SELL |
| IMUX | Immunic, Inc. | $208M | 38 | HOLD |
Peer medians: ROE -21.2% · P/E 27.1x · Gross margin 44.5%